In this study, the expression of CDC42 was detected in patients with AIS during a 3-year follow-up period with the aim of evaluating the longitudinal changes of CDC42 and its correlation with disease severity, Th1/2/17 cells, and the prognosis in patients with AIS. The gene discussed is CDC42; the disease is androgen insensitivity syndrome.